Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683666 | 0.94 | PPARG (0.50) | AGTR2PPARGAGTR1 | |
| SCHEMBL683670 | 0.92 | AGTR1 (0.49) | PPARGAGTR1 | |
| SCHEMBL682534 | 0.91 | AGTR2 (0.62) | AGTR2PPARGAGTR1 | |
| SCHEMBL684052 | 0.89 | AGTR2 (0.60) | AGTR2PPARGKCNH2AGTR1 | |
| SCHEMBL7012387 | 0.82 | AGTR1 (0.38) | AGTR2PPARGAGTR1 | |
| SCHEMBL7016142 | 0.82 | AGTR1 (0.39) | AGTR2PPARGAGTR1 | |
| SCHEMBL684048 | 0.82 | AGTR2 (0.57) | AGTR2PPARGKCNH2AGTR1 | |
| SCHEMBL683658 | 0.80 | AGTR2 (0.75) | AGTR2PPARGKCNH2AGTR1 | |
| SCHEMBL12894783 | 0.80 | AGTR1 (0.50) | PPARGAGTR1 | |
| SCHEMBL9032973 | 0.79 | AGTR1 (0.41) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR2 2610/4885PPARG 156/4885KCNH2 4093/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR2 9/4885PPARG 622/4885KCNH2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.